SG11201912243PA - Methods and compositions for treating a bleeding event in a subject having hemophilia - Google Patents

Methods and compositions for treating a bleeding event in a subject having hemophilia

Info

Publication number
SG11201912243PA
SG11201912243PA SG11201912243PA SG11201912243PA SG11201912243PA SG 11201912243P A SG11201912243P A SG 11201912243PA SG 11201912243P A SG11201912243P A SG 11201912243PA SG 11201912243P A SG11201912243P A SG 11201912243PA SG 11201912243P A SG11201912243P A SG 11201912243PA
Authority
SG
Singapore
Prior art keywords
hemophilia
compositions
treating
subject
methods
Prior art date
Application number
SG11201912243PA
Inventor
Akin Akinc
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG11201912243PA publication Critical patent/SG11201912243PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
SG11201912243PA 2017-07-10 2018-07-10 Methods and compositions for treating a bleeding event in a subject having hemophilia SG11201912243PA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762530518P 2017-07-10 2017-07-10
US201762599223P 2017-12-15 2017-12-15
US201862614111P 2018-01-05 2018-01-05
US201862673424P 2018-05-18 2018-05-18
PCT/US2018/041400 WO2019014187A1 (en) 2017-07-10 2018-07-10 Methods and compositions for treating a bleeding event in a subject having hemophilia

Publications (1)

Publication Number Publication Date
SG11201912243PA true SG11201912243PA (en) 2020-01-30

Family

ID=63036452

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912243PA SG11201912243PA (en) 2017-07-10 2018-07-10 Methods and compositions for treating a bleeding event in a subject having hemophilia

Country Status (14)

Country Link
US (2) US20200163987A1 (en)
EP (1) EP3651852A1 (en)
JP (2) JP2020530442A (en)
KR (1) KR20200026960A (en)
CN (1) CN111093771A (en)
AU (1) AU2018301801A1 (en)
BR (1) BR112020000400A2 (en)
CA (1) CA3069150A1 (en)
CO (1) CO2020001354A2 (en)
IL (1) IL271646A (en)
SG (1) SG11201912243PA (en)
TW (1) TW201920670A (en)
UY (1) UY37803A (en)
WO (1) WO2019014187A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115942940A (en) 2020-06-22 2023-04-07 建新公司 Methods and compositions for treating hemophilia
WO2022076835A1 (en) * 2020-10-09 2022-04-14 Dyax Corp. Methods and apparatuses for modeling adamts13 and von willebrand factor interactions
WO2022120291A1 (en) * 2020-12-06 2022-06-09 Genzyme Corporation Treatment of hemophilia with fitusiran
JP2023552554A (en) * 2020-12-06 2023-12-18 ジェンザイム・コーポレーション Treatment of hemophilia with fitusiran
TW202342065A (en) 2021-12-22 2023-11-01 美商健臻公司 Methods and compositions for treating hemophilia
WO2023240199A2 (en) 2022-06-08 2023-12-14 Genzyme Corporation Treatment of hemophilia with fitusiran
WO2023240193A2 (en) 2022-06-08 2023-12-14 Genzyme Corporation Treatment of hemophilia with fitusiran in pediatric patients

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546096B2 (en) * 2008-08-22 2013-10-01 Baxter International Inc. Method for identifying a non-anticoagulant sulfated polysaccharide which enhances blood coagulation dependence on FXI
TW201607559A (en) * 2014-05-12 2016-03-01 阿尼拉製藥公司 Methods and compositions for treating a SERPINC1-associated disorder
WO2016085852A1 (en) * 2014-11-24 2016-06-02 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
IL259795B2 (en) * 2015-12-07 2024-04-01 Genzyme Corp Methods and compositions for treating a serpinc1-associated disorder

Also Published As

Publication number Publication date
JP2020530442A (en) 2020-10-22
TW201920670A (en) 2019-06-01
CO2020001354A2 (en) 2020-05-29
RU2020105876A (en) 2021-08-10
CA3069150A1 (en) 2019-01-17
AU2018301801A1 (en) 2020-02-06
IL271646A (en) 2020-02-27
BR112020000400A2 (en) 2020-07-14
CN111093771A (en) 2020-05-01
US20200163987A1 (en) 2020-05-28
RU2020105876A3 (en) 2021-11-16
UY37803A (en) 2019-02-28
US20230158058A1 (en) 2023-05-25
JP2023123756A (en) 2023-09-05
KR20200026960A (en) 2020-03-11
EP3651852A1 (en) 2020-05-20
WO2019014187A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
IL271646A (en) Methods and compositions for treating a bleeding event in a subject having hemophilia
IL245778B (en) Methods and compositions for treating hemophilia
HK1256602A1 (en) Compositions and methods for treating pterygium
HK1245632A1 (en) Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
IL269620A (en) Compositions and methods for treating phenylketonuria
HK1248590A1 (en) Compositions and methods for treating anemia
HUE054204T2 (en) Compositions and methods for treating and preventing inflammation
HK1258696A1 (en) Novel compositions and methods for treating or preventing dermal disorders
PL3261644T3 (en) Compositions and methods for treating retinal degradation
SG10201708547YA (en) Compositions and methods for treating and preventing macular degeneration
PL3280423T3 (en) Synergistic glycocalyx treatment compositions and methods
IL271464A (en) Nk-1 antagonist compositions and methods for use in treating depression
HK1258374A1 (en) Hemostatic composition and hemostatic method using hemostatic composition
EP3356598A4 (en) Compositions and methods for treating filler in papermaking
IL261010B (en) Compositions and methods for treating chronic wounds
ZA201605109B (en) Compositions and methods for treating neutropenia
HK1256167A1 (en) Compositions comprising 15-hepe for use in treating or preventing cancer and neurologic disease
ZA201802268B (en) Methods and compositions for preventing or treating cancer
MX2018004632A (en) Methods and compositions for treating traumatic brain injury.
IL272945A (en) Topical compositions and methods for treatment
IL257407A (en) Compositions and methods for treating wounds
EP3429563A4 (en) Compositions and methods for treating compulsive-like behavior in a subject
GB201716239D0 (en) Compositions and methods for treating pseudoaneurysm
EP3397271A4 (en) Compositions and methods for treating retinopathy
GB201521083D0 (en) Compositions for treatment and methods thereof